Currently Viewing:
Newsroom
Currently Reading
A Significant Unmet Mental Health Care Need Exists for Patients With COPD
August 25, 2019 – Kelly Davio
Medicaid Expansion Linked to Increased HIV Testing
August 24, 2019 – Jaime Rosenberg
5 Things to Look for at the European Society of Cardiology 2019 Congress
August 23, 2019 – Mary Caffrey
Phase I Pancreatic Cancer Trial Identifies Effective Combination Treatment
August 23, 2019 – Alison Rodriguez
AJMC® in the Press, August 23, 2019
August 23, 2019 – AJMC Staff
Fatal AEs Associated With Alemtuzumab for MS May Occur More Frequently Than Previously Thought
August 23, 2019 – Laura Joszt
What We're Reading: ACA Plan Offerings Expand; Combo Pill Cuts CV Events; Biosimilar Savings
August 23, 2019 – AJMC Staff
This Week in Managed Care: August 23, 2019
August 23, 2019
HHS Proposes Easing Privacy Restrictions for Patients With History of Substance Use Disorder
August 22, 2019 – Jaime Rosenberg

Velcade Approved for Mantle Cell Lymphoma in Europe

The drug has been approved for treatment-naive patients who are ineligible for transplant.
European regulators have expanded the label on Johnson & Johnson’s multiple myeloma drug Velcade to cover mantle cell lymphoma.

Specifically, the European Commission has approved a variation to the terms of J&J unit Janssen’s marketing authorisation of Velcade (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for adults with previously-untreated MCL who are unsuitable for blood stem-cell transplantation. The drug is currently indicated in Europe for multiple myeloma, either as monotherapy or in combinations.

Thomas Stark, head of medical affairs at Janssen Europe, Middle East and Africa, noted that “we already offer Imbruvica (ibrutinib) as a second-line treatment in MCL and are pleased to be able to provide additional treatment options for this disease”. Velcade is already approved for MCL in the USA, marketed by Takeda’s Millennium unit. 


Complete report on PharmacyTimes: http://bit.ly/16Kaawc

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up